Enzene Announces Official Inauguration of New U.S. Biomanufacturing Facility
Located in Hopewell, N.J., the new facility signifies the first major manufacturing investment for Enzene within the U.S., strengthening the company’s commitment to supporting innovation and supply chain resilience in the country.
Fully integrated, end-to-end CDMO, Enzene, has announced the official inauguration of its 80,000 sq. ft. state-of-the-art biomanufacturing facility in Hopewell, N.J., by the State’s Governor, Phil Murphy (1). The establishment of this new facility marks a significant milestone for the company as it expands its biotech capabilities in the U.S.
“When Enzene — one of India’s most promising biotechnological companies — decided to launch its very first U.S. manufacturing base, they knew there was nowhere better to do it than right here in New Jersey. Their decision reflects not only our state’s strength as a hub for global business and innovation, but also the deep cultural ties that bind New Jersey and India,” said Governor Murphy, in a company press release (1). “This state-of-the-art facility represents the future of advanced manufacturing — ultimately creating hundreds of jobs and generating USD 50 million in investment. As Enzene expands its presence here in New Jersey, we remain committed to supporting the company as it builds the world-class manufacturing ecosystem of tomorrow.”
The new facility will not only support fed-batch drug substance manufacturing but will also make use of the company’s modular, fully-connected continuous manufacturing (FCCM) platform, EnzeneX 2.0.
“We are proud to bring our global expertise to the U.S. and contribute to the advancement of biopharmaceutical manufacturing,” added Himanshu Gadgil, Ph.D., CEO of Enzene, in the press release (1). “Our first-to-market manufacturing technology is forging a new path in biologics manufacturing that will provide a cost-efficient, high yield, U.S.-based biomanufacturing solution for biopharmaceutical innovators, and complement our facilities in India to provide global supply solutions.”
“Enzene has demonstrated that it is committed to providing transformative innovations that can have a positive impact on biopharmaceutical development. In pioneering small-footprint, scalable biomanufacturing, Enzene is providing benefits in sustainability, cost, and ultimately to the global healthcare ecosystem,” commented Sandeep Singh, Chairman of the Board at Enzene and Managing Director of Alkem Laboratories, in the press release (1). “This latest step in the company’s strategic expansion plans extends Enzene’s commitment to providing equitable access to cost-effective manufacturing for early-stage biologics developers in the U.S. and beyond.”
Launched at CPHI Milan in 2024, EnzeneX offers users uninterrupted processing from perfusion to final drug substance (2). The platform streamlines production, improves productivity and target protein concentrations, and mitigates risks associated with batch-to-batch transfers by using high titer clones. Additionally, the technology leverages optimized cell media to boost cell productivity and efficiency, and incorporates process analytical technology to enable real-time monitoring and control for consistent quality and optimized processing.
“Our latest innovation in fully-connected continuous manufacturing can be tailored for a broad range of modalities and media formulations to boost cell productivity and efficiency,” said Gadgil in a press release about the launch of EnzeneX (2). “Lower operational costs and higher productivity can enable up to 50% reductions in overall production cost per gram, and we are on target to achieve a game-changing benchmark by 2025.”
References
Enzene. Governor Murphy Inaugurates New U.S. Continuous Biomanufacturing Facility of India-Based Enzene. Press Release, Sept. 4, 2025.
Enzene. Enzene Launches EnzeneX 2.0: The Next Generation of its Fully-Connected Continuous Manufacturing (FCCM) Technology for Biologics at CPHI Milan 2024. Press Release, Oct. 4, 2024.